- Home
- NERV vs RLMD Comparison
NERV vs RLMD Comparison
Compare NERV & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- RLMD
- Stock Information
- Founded
- NERV 2007
- RLMD 2004
- Country
- NERV United States
- RLMD United States
- Employees
- NERV N/A
- RLMD N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- RLMD Health Care
- Exchange
- NERV Nasdaq
- RLMD Nasdaq
- Market Cap
- NERV 10.7M
- RLMD 11.5M
- IPO Year
- NERV 2014
- RLMD N/A
- Fundamental
- Price
- NERV $1.61
- RLMD $0.30
- Analyst Decision
- NERV Hold
- RLMD Hold
- Analyst Count
- NERV 1
- RLMD 4
- Target Price
- NERV $5.00
- RLMD $4.25
- AVG Volume (30 Days)
- NERV 15.1K
- RLMD 382.7K
- Earning Date
- NERV 04-30-2025
- RLMD 03-27-2025
- Dividend Yield
- NERV N/A
- RLMD N/A
- EPS Growth
- NERV N/A
- RLMD N/A
- EPS
- NERV 0.19
- RLMD N/A
- Revenue
- NERV N/A
- RLMD N/A
- Revenue This Year
- NERV N/A
- RLMD N/A
- Revenue Next Year
- NERV N/A
- RLMD N/A
- P/E Ratio
- NERV $8.95
- RLMD N/A
- Revenue Growth
- NERV N/A
- RLMD N/A
- 52 Week Low
- NERV $1.42
- RLMD $0.24
- 52 Week High
- NERV $3.69
- RLMD $5.09
- Technical
- Relative Strength Index (RSI)
- NERV 41.00
- RLMD 50.05
- Support Level
- NERV $1.54
- RLMD $0.26
- Resistance Level
- NERV $1.89
- RLMD $0.32
- Average True Range (ATR)
- NERV 0.11
- RLMD 0.02
- MACD
- NERV 0.00
- RLMD 0.00
- Stochastic Oscillator
- NERV 22.68
- RLMD 67.34
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.